Status:
COMPLETED
A Study to Assess How Well Certolizumab Pegol Works in Patients With Moderate to Severe Plaque Psoriasis as Part of Routine Clinical Practice
Lead Sponsor:
UCB Biopharma SRL
Conditions:
Plaque Psoriasis
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of the study is to assess the effectiveness of certolizumab pegol in patients with moderate to severe plaque psoriasis as part of routine clinical practice.
Eligibility Criteria
Inclusion
- The patient is ≥18 years of age at observational point 1
- The patient must have a clinical diagnosis of moderate to severe Plaque psoriasis according to the diagnostic criteria used by the physician in routine clinical practice
- The patient has an available PASI assessment prior to the first certolizumab pegol dose according to the standard of care
- The patient must be newly prescribed with certolizumab pegol
- If a patient is participating in an ongoing investigational study, then he/she will not be able to take part in this study
Exclusion
- Not applicable
Key Trial Info
Start Date :
August 21 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 2 2022
Estimated Enrollment :
412 Patients enrolled
Trial Details
Trial ID
NCT04053881
Start Date
August 21 2019
End Date
December 2 2022
Last Update
January 23 2023
Active Locations (79)
Enter a location and click search to find clinical trials sorted by distance.
1
Ps0026 101
Brussels, Belgium
2
Ps0026 103
Brussels, Belgium
3
Ps0026 107
Brussels, Belgium
4
Ps0026 102
Leuven, Belgium